Fertility outcome of breast cancer and Hodgkin’s lymphoma female survivors: a growing clinical challenge for gynecologists and oncologists

References

• Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996;14:1718–29
   PubMed Web of Science ®Google Scholar
• Minton SE, Munster PN. Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control 2002;9:466–72
   PubMedGoogle Scholar
• Mrozek E, Shapiro CL. Survivorship and complications of treatment in breast cancer. Clin Adv Hematol Oncol. 2005;3:211-22
   PubMedGoogle Scholar
• Fornier MN, Modi S, Panageas KS, et al. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer 2005;104:1575–9
   PubMed Web of Science ®Google Scholar
• Behringer K, Breuer K, Reineke T, et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2005;23:7555–64
   PubMed Web of Science ®Google Scholar
• Friedman DL, Constine LS. Late effects of treatment for Hodgkin lymphoma. J Natl Compr Cancer Network 2006;4:249–57
   PubMedGoogle Scholar
• Haukvik UK, Dieset I, Bjoro T, et al. Treatment-related premature ovarian failure as a long-term complication after Hodgkin's lymphoma. Ann Oncol 2006;17:1428–33
   PubMed Web of Science ®Google Scholar
• De Bruin ML, Huisbrink J, Hauptmann M, et al. Treatment-related risk factors for premature menopause following Hodgkin lymphoma. Blood 2008;111:101–8
   PubMed Web of Science ®Google Scholar
• Gerber B, Dieterich M, Müller H, et al. Controversies in preservation of ovary function and fertility in patients with breast cancer. Breast Cancer Res Treat 2008;108:1–7
   PubMed Web of Science ®Google Scholar
• Okanami Y, Ito Y, Watanabe C, et al. Incidence of chemotherapy-induced amenorrhea in premenopausal patients with breast cancer following adjuvant anthracycline and taxane. Breast Cancer 2011;18:182–8
   PubMed Web of Science ®Google Scholar
• Behringer K, Mueller H, Goergen H, et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. J Clin Oncol 2013;31:231–9
   PubMed Web of Science ®Google Scholar
• Wallace WH, Thomson AB, Saran F, et al. Predicting age of ovarian failure after radiation to a field that includes the ovaries. Int J Radiat Oncol Biol Phys 2005;62:738–44
   PubMed Web of Science ®Google Scholar
• Shahin MS, Puscheck E. Reproductive sequelae of cancer treatment. Obstet Gynecol Clin North Am 1998;25:423–33
   PubMed Web of Science ®Google Scholar
• Levine MN, Bramwell VH, Pritchard KI, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998;16:2651–8
   PubMed Web of Science ®Google Scholar
• Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006;24:2917–31
   Google Scholar
• Tham YL, Sexton K, Weiss H, et al. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol 2007;30:126–32
   PubMed Web of Science ®Google Scholar
• Sklar CA, Mertens AC, Mitby P, et al. Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. J Natl Cancer Inst 2006;98:890–6
   PubMed Web of Science ®Google Scholar
• Dillon KE, Sammel MD, Prewitt M, et al. Pretreatment antimüllerian hormone levels determine rate of post therapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy. Fertil Steril 2013:99:477–83
   PubMed Web of Science ®Google Scholar
• van der Kaaij MA, van Echten-Arends J, Simons AH, et al. Fertility preservation after chemotherapy for Hodgkin lymphoma. Hematol Oncol 2010;28:168–79
   PubMed Web of Science ®Google Scholar
• Damewood MD, Grochow LB. Prospects of fertility after chemotherapy or radiation for neoplastic disease. Fertil Steril 1986;45:443–9
   PubMed Web of Science ®Google Scholar
• Anderson RA, Themmen AP, Al-Qahtani A, et al. The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod 2006;21:2583–92
   PubMed Web of Science ®Google Scholar
• Lee MM, Donahoe PK, Hasegawa T, et al. Mullerian inhibiting substance in humans: normal levels from infancy to adulthood. J Clin Endocrinol Metab 1996;81:571–6
   PubMed Web of Science ®Google Scholar
• de Vet A, Laven JS, de Jong FH, et al. Antimüllerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril 2002;77:357–62
   PubMed Web of Science ®Google Scholar
• Knauff EA, Eijkemans MJ, Lambalk CB, et al. Anti-Mullerian hormone, inhibin B, and antral follicle count in young women with ovarian failure. J Clin Endocrinol Metab 2009;94:786–92
   Google Scholar
• Behringer K, Thielen I, Mueller H, et al. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Ann Oncol 2012;23:1818–25
   PubMed Web of Science ®Google Scholar
• Lawrenz B, Fehm T, von Wolff M, et al. Reduced pretreatment ovarian reserve in premenopausal female patients with Hodgkin lymphoma or non-Hodgkin-lymphoma–evaluation by using anti-Müllerian hormone and retrieved oocytes. Fertil Steril 2012;98:141–4
   PubMed Web of Science ®Google Scholar
• Iwase A, Sugita A, Hirokawa W, et al. Anti-Müllerian hormone as a marker of ovarian reserve following chemotherapy in patients with gestational trophoblastic neoplasia. Eur J Obstet Gynecol Reprod Biol 2013;167:194--8
   Google Scholar
• Dillon KE, Sammel MD, Prewitt M, et al. Pretreatment anti-Müllerian hormone levels determine rate of post therapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy. Fertil Steril 2013;99:477–83
   PubMed Web of Science ®Google Scholar
• Chapman RM, Sutcliffe SB. Protection of ovarian function by oral contraceptives in women receiving chemotherapy for Hodgkin's disease. Blood 1981;58:849–51
   PubMed Web of Science ®Google Scholar
• Whitehead E, Shalet SM, Blackledge G, et al. The effect of combination chemotherapy on ovarian function in women treated for Hodgkin's disease. Cancer 1983;52:988–93
   PubMed Web of Science ®Google Scholar
• Ataya K, Rao LV, Lawrence E, et al. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. Biol Reprod 1995;52:365–72
   PubMed Web of Science ®Google Scholar
• Blumenfeld Z, Avivi I, Linn S, et al. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. Hum Reprod 1996;11:1620–6
   PubMed Web of Science ®Google Scholar
• Recchia F, Saggio G, Amiconi G, et al. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer 2006;106:514–23
   PubMed Web of Science ®Google Scholar
• Badawy A, Elnashar A, El-Ashry M, et al. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 2009;91:694–97
   PubMed Web of Science ®Google Scholar
• Sverrisdottir A, Nystedt M, Johansson H, et al. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat 2009;117:561–7
   Web of Science ®Google Scholar
• Clowse ME, Behera MA, Anders CK, et al. Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. J Womens Health 2009;18:311–19
   Google Scholar
• Leonard RC, Adamson D, Anderson R, et al. The OPTION trial of adjuvant ovarian protection by goserelin in adjuvant chemotherapy for early breast cancer. J Clin Oncol 2010;28: abstract 590
   PubMed Web of Science ®Google Scholar
• Del Mastro L, Boni L, Michelotti A, et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA 2011;306:269–76
   PubMed Web of Science ®Google Scholar
• Gerber B, von Minckwitz G, Stehle H, et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol 2011;29:2334–41
   PubMed Web of Science ®Google Scholar
• Chen H, Li J, Cui T, et al. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal women. Cochrane Database Syst Rev 2011;9:CD008018
   Google Scholar
• Munster PN, Moore AP, Ismail-Khan R, et al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol 2012;30:533–8
   PubMed Web of Science ®Google Scholar
• Elgindy EA, El-Haieg DO, Khorshid OM, et al. Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial. Obstet Gynecol 2013;121:78–86
   PubMed Web of Science ®Google Scholar
• Wong M, O'Neill S, Walsh G, et al. Goserelin with chemotherapy to preserve ovarian function in pre-menopausal women with early breast cancer: menstruation and pregnancy outcomes. Ann Oncol 2013;24:133–8
   PubMed Web of Science ®Google Scholar
• Yang B, Shi W, Yang J, et al. Concurrent treatment with gonadotropin-releasing hormone agonists for chemotherapy-induced ovarian damage in premenopausal women with breast cancer: A meta-analysis of randomized controlled trials. Breast 2013;22:150--7
   Google Scholar
• Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? the role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries. Oncologist 2007;12:1044–54
   PubMed Web of Science ®Google Scholar
• Lobo RA. Potential options for preservation of fertility in women. N Engl J Med 2005;353:64–73
   PubMed Web of Science ®Google Scholar
• Kitajima Y, Endo T, Nagasawa K, et al. Hyperstimulation and a gonadotropin-releasing hormone agonist modulate ovarian vascular permeability by altering expression of the tight junction protein claudin-5. Endocrinology 2006;147:694–9
   PubMed Web of Science ®Google Scholar
• Imai A, Sugiyama M, Furui T, et al. Direct protection by a gonadotropin-releasing hormone analog from doxorubicin-induced granulosa cell damage. Gynecol Obstet Invest 2007;3:102–6
   Google Scholar
• Tilly JL. Commuting the death sentence: How oocytes strive to survive. Nat Rev Mol Cell Biol 2001;2:838–48
   PubMed Web of Science ®Google Scholar
• Morita Y, Perez GI, Paris F, et al. Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy. Nat Med 2000;6:1109–14
   PubMed Web of Science ®Google Scholar
• Hartman M, Liu J, Czene K, et al. Birth rates among female cancer survivors: a population-based cohort study in Sweden. Cancer 2013;119:1892--9
   PubMed Web of Science ®Google Scholar
• Kiserud CE, Fossa A, Holte H, et al. Post-treatment parenthood in Hodgkin's lymphoma survivors. Br J Cancer 2007;96:1442–9
   PubMed Web of Science ®Google Scholar
• Aisner J, Wiernik PH, Pearl P. Pregnancy outcome in patients treated for Hodgkin's disease. J Clin Oncol 1993;11:507–12
   PubMed Web of Science ®Google Scholar
• Hodgson DC, Pintilie M, Gitterman L, et al. Fertility among female Hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy. Hematol Oncol 2007;25:11–15
   PubMed Web of Science ®Google Scholar
• De Sanctis V, Filippone FR, Alfò M, et al. Impact of different treatment approaches on pregnancy outcomes in 99 women treated for Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2012;84:755–61
   PubMed Web of Science ®Google Scholar
• Valentgas P, Daling JR, Malone KE, et al. Pregnancy after breast carcinoma: outcomes and influence on mortality. Cancer 1999;85:2424–32
   PubMed Web of Science ®Google Scholar
• Durrieu G, Rigal M, Bugat R, et al. Fertility and outcomes of pregnancy after chemotherapy in a sample of childbearing aged women. Fundam Clin Pharmacol 2004;18:573–9
   PubMed Web of Science ®Google Scholar
• Blakely LJ, Buzdar AU, Lozada JA, et al. Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence. Cancer 2004;100:465–9
   PubMed Web of Science ®Google Scholar
• Park M, Davidson R, Fox K. Preservation of fertility and the impact of subsequent pregnancy in patients with premenopausal breast cancer. Semin Oncol 2006;33:664–71
   PubMed Web of Science ®Google Scholar
• Ives A, Saunders C, Bulsara M, et al. Pregnancy after breast cancer: population based study. BMJ 2007;334:194
   PubMed Web of Science ®Google Scholar
• Gadducci A, Cosio S, Genazzani AR. Ovarian function and childbearing issues in breast cancer survivors. Gynecol Endocrinol 2007;23:625–31
   PubMed Web of Science ®Google Scholar
• Petrek JA, Naughton MJ, Case LD, et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 2006;24:1045–51
   PubMed Web of Science ®Google Scholar
• Oktay K. Evidence for limiting ovarian tissue harvesting for the purpose of transplantation to women younger than 40 years of age. J Clin Endocrinol Metab 2002;87:1907–8
   PubMed Web of Science ®Google Scholar
• Lucena E, Bernal DP, Lucena C, et al. Successful ongoing pregnancies after vitrification of oocytes. Fertil Steril 2006;85:108–11
   PubMed Web of Science ®Google Scholar
• Dolmans MM, Donnez J, Camboni A, et al. IVF outcome in patients with orthotopically transplanted ovarian tissue. Hum Reprod 2009;24:2778–87
   PubMed Web of Science ®Google Scholar
• Oktem O, Oktay K. Fertility preservation for breast cancer patients. Semin Reprod Med 2009;27:486–92
   PubMed Web of Science ®Google Scholar
• Fabbri R, Vicenti R, Magnani V, et al. Cryopreservation of ovarian tissue in breast cancer patients: 10 years of experience. Future Oncol 2012;8:1613–19
   PubMed Web of Science ®Google Scholar
• Berwanger AL, Finet A, El Hachem H, et al. New trends in female fertility preservation: in vitro maturation of oocytes. Future Oncol 2012;8:1567–73
   PubMed Web of Science ®Google Scholar
• Blumenfeld Z. Chemotherapy and fertility. Best Pract Res Clin Obstet Gynaecol 2012;26:379–90
   PubMed Web of Science ®Google Scholar
• McCarthy NJ. Care of the breast cancer survivor: increased survival rates present a new set of challenges. Postgrad Med 2004;116:39–40
   Google Scholar
• Braun M, Hasson-Ohayon I, Perry S, et al. Motivation for giving birth after breast cancer. Psychooncology 2005;14:282–96
   PubMed Web of Science ®Google Scholar
• Connell S, Patterson C, Newman B. A qualitative analysis of reproductive issues raised by young Australian women with breast cancer. Health Care Women Int 2006;27:94–110
   PubMedGoogle Scholar